What is HC Wainwright’s Forecast for CRBP Q1 Earnings?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) – HC Wainwright issued their Q1 2026 earnings estimates for shares of Corbus Pharmaceuticals in a research note issued on Thursday, November 13th. HC Wainwright analyst A. Maldonado anticipates that the biopharmaceutical company will earn ($1.31) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($4.23) per share. HC Wainwright also issued estimates for Corbus Pharmaceuticals’ Q2 2026 earnings at ($1.32) EPS, Q3 2026 earnings at ($1.34) EPS and Q4 2026 earnings at ($1.37) EPS.

A number of other research firms also recently issued reports on CRBP. Weiss Ratings reissued a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a research report on Wednesday, October 8th. Wedbush lifted their price objective on Corbus Pharmaceuticals from $31.00 to $38.00 and gave the company an “outperform” rating in a research note on Monday, October 20th. Piper Sandler reiterated an “overweight” rating and set a $51.00 target price on shares of Corbus Pharmaceuticals in a report on Monday, October 20th. Oppenheimer dropped their target price on shares of Corbus Pharmaceuticals from $56.00 to $53.00 and set an “outperform” rating for the company in a research report on Wednesday, August 6th. Finally, Royal Bank Of Canada reduced their price target on shares of Corbus Pharmaceuticals from $55.00 to $53.00 and set an “outperform” rating on the stock in a research report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Corbus Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $44.38.

Corbus Pharmaceuticals Price Performance

CRBP stock opened at $11.07 on Friday. The company has a market cap of $135.66 million, a price-to-earnings ratio of -2.33 and a beta of 2.69. The business has a fifty day simple moving average of $13.36 and a 200-day simple moving average of $10.12. Corbus Pharmaceuticals has a 52 week low of $4.64 and a 52 week high of $20.56.

Corbus Pharmaceuticals (NASDAQ:CRBP) last posted its quarterly earnings results on Wednesday, November 12th. The biopharmaceutical company reported ($1.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.80) by ($0.10).

Hedge Funds Weigh In On Corbus Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. grew its position in shares of Corbus Pharmaceuticals by 2.1% during the third quarter. Vanguard Group Inc. now owns 612,030 shares of the biopharmaceutical company’s stock worth $7,742,000 after buying an additional 12,535 shares in the last quarter. Exome Asset Management LLC acquired a new position in Corbus Pharmaceuticals during the 1st quarter worth $1,538,000. Armistice Capital LLC increased its position in shares of Corbus Pharmaceuticals by 5.9% in the 1st quarter. Armistice Capital LLC now owns 250,000 shares of the biopharmaceutical company’s stock worth $1,328,000 after purchasing an additional 14,000 shares during the last quarter. Comerica Bank raised its stake in shares of Corbus Pharmaceuticals by 20,000,000.0% in the 1st quarter. Comerica Bank now owns 200,001 shares of the biopharmaceutical company’s stock valued at $1,062,000 after purchasing an additional 200,000 shares in the last quarter. Finally, Acadian Asset Management LLC acquired a new stake in shares of Corbus Pharmaceuticals in the 1st quarter valued at about $1,007,000. 64.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Corbus Pharmaceuticals

In related news, CEO Yuval Cohen sold 18,660 shares of the stock in a transaction dated Friday, October 24th. The stock was sold at an average price of $17.01, for a total value of $317,406.60. Following the completion of the transaction, the chief executive officer owned 138,187 shares of the company’s stock, valued at approximately $2,350,560.87. This represents a 11.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Sean F. Moran sold 12,981 shares of the firm’s stock in a transaction that occurred on Friday, October 24th. The shares were sold at an average price of $17.02, for a total value of $220,936.62. Following the sale, the chief financial officer owned 73,313 shares of the company’s stock, valued at approximately $1,247,787.26. This trade represents a 15.04% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 41,674 shares of company stock valued at $713,870. 4.00% of the stock is currently owned by corporate insiders.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.